Askbio Inc
Clinical trials sponsored by Askbio Inc, explained in plain language.
A gene therapy company, subsidiary of Bayer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Gene therapy injection aims to repair failing hearts
Disease control OngoingThis study tests a one-time gene therapy called AB-1002, given directly into the heart arteries, for people with advanced heart failure (NYHA Class III). The goal is to see if it can improve heart function, reduce symptoms, and lower the risk of death or hospitalization. About 15…
Phase: PHASE2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Gene therapy AB-1005: how safe is it years later?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 132 people with Parkinson's disease or multiple system atrophy who previously received the gene therapy AB-1005. Researchers will track safety and how well the treatment works over the long term. No new treatments are given; it's purely observational.
Sponsor: AskBio Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC